Supernus Pharmaceuticals and Indivior agreed to an all-stock merger to form a CNS-focused drugmaker based in Rockville, Maryland. The combined company keeps the Supernus name, aiming to concentrate resources on central nervous system diseases. The transaction also signals continued consolidation among specialty biopharma companies targeting neuropsychiatric and neurological markets, where development costs and competitive differentiation pressures have intensified. Both sides characterized the move as a portfolio-strengthening step, aligning corporate structures around CNS programs and development capabilities.